Back to Journals » Infection and Drug Resistance » Volume 13

Clinical Characteristics of Pneumocystis Pneumonia After Parental Renal Transplantation

Authors Li T, Shi J, Xu F, Xu X

Received 9 October 2019

Accepted for publication 25 December 2019

Published 8 January 2020 Volume 2020:13 Pages 81—88

DOI https://doi.org/10.2147/IDR.S234039

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Eric Nulens


Tiantian Li,* Junqin Shi,* Fei Xu, Xiaoling Xu

Respiratory and Critical Care Medicine, Affiliated Provincial Hospital to Anhui Medical University, Hefei, Anhui, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Xiaoling Xu
Respiratory and Critical Care Medicine, Affiliated Provincial Hospital to Anhui Medical University, No. 17 Lujiang Road, Hefei, Anhui 230001, People’s Republic of China
Tel +86 189 6378 9002
Email xxlahh08@163.com

Purpose: To analyze the clinical characteristics of Pneumocystis pneumonia (PCP) in renal transplant recipients, identify early sensitivity indicators, and optimize clinical strategies.
Patients and Methods: We retrospectively analyzed clinical data for 24 patients with confirmed PCP who underwent renal transplantation (RT) between 2010 and 2019, encompassing a mean follow-up of 29 (range, 11– 49) d.
Results: A 71% incidence was observed for PCP during the first 6 months after RT. Progressive dyspnea (79%) was the most common symptom, followed by fever (75%) and dry cough (67%). In the initial phase of PCP, the most frequent computerized tomography (CT) finding was the presence of symmetric, apically distributed ground-glass opacities. Nine of 11 patients (82%) were diagnosed by induced sputum testing, 14 of 17 (82%) by bronchoalveolar lavage, and 1 of 24 (4%) by sputum smear. The 1,3-β-D-glucan level was elevated (mean, 259.16 ± 392.34 pg/mL) in 80% of patients, while 75% had elevated C-reactive protein levels (median, 37.85 mg/L). Two of 18 patients (11%) were positive for cytomegalovirus. All patients were treated with trimethoprim-sulfamethoxazole (3 doses of 1– 6 g/kg) and third-generation cephalosporin or moxifloxacin monotherapy to prevent bacterial infection. The methylprednisolone dose (40– 400 mg/d) varied according to illness. Most patients were treated using a nasal cannula or oxygen mask, and 2 by mechanical ventilation. CT showed improved lesions after treatment, and completely absorbed lesions or residual fibrosis at follow-up. The mean hospitalization cost was 14,644.73 ± 11,101.59 RMB.
Conclusion: Peak PCP incidence occurred during the first 6 months after surgery. Progressive dyspnea, fever, and dry cough are important indicators for PCP. Bilateral and diffuse ground-glass opacities involving both lung apexes are often the first indication for PCP diagnosis. Induced sputum testing may be the method-of-choice for pathogen detection. The cure rate can be improved through early antipathogen, glucocorticoid, and preventive anti-infection therapies, as well as respiratory support.

Keywords: renal transplantation, Pneumocystis jirovecii, clinical characteristics, optimize clinical strategies


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]